48,830
edits
m (w) |
(+TKI) |
||
Line 2: | Line 2: | ||
==Drugs== | ==Drugs== | ||
*Gefitinib (Iressa).<ref name=pmid20855837/> | *[[Gefitinib]] (Iressa).<ref name=pmid20855837/> | ||
*Erlotinib (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref> | *[[Erlotinib]] (Tarceva)).<ref name=pmid20855837>{{cite journal |author=Sun Y, Ren Y, Fang Z, ''et al.'' |title=Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases |journal=J. Clin. Oncol. |volume=28 |issue=30 |pages=4616–20 |year=2010 |month=October |pmid=20855837 |doi=10.1200/JCO.2010.29.6038 |url=}}</ref> | ||
Note: | |||
*Both ''gefitinib'' and ''erlotinib'' are also classified as ''tyrosine kinase inhibitors'' (TKI). | |||
==Use== | ==Use== |
edits